OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time BOERSE MUENCHEN 14:37:26 03/07/2024 BST | ||
| 1.58 EUR | +10.49% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 1.58 | +10.49% |
| 02/07/24 | 1.43 | +21.19% |
| 01/07/24 | 1.18 | -17.48% |
| 28/06/24 | 1.43 | +9.16% |
| 27/06/24 | 1.31 | -2.96% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 02:37 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | HS6UVX |
| ISIN | DE000HS6UVX3 |
| Date issued | 07/06/2024 |
| Strike | 155.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.32 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.64 € |
|---|---|
| Lowest since issue | 0.97 € |
| Spread | 0.01 € |
| Spread % | 0.54% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Certificates
- Certificat
